EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment

MLA

Debasmita Dutta, et al. “EpCAM-Targeted Betulinic Acid Analogue Nanotherapy Improves Therapeutic Efficacy and Induces Anti-Tumorigenic Immune Response in Colorectal Cancer Tumor Microenvironment.” Journal of Biomedical Science, vol. 31, no. 1, Aug. 2024, pp. 1–29. EBSCOhost, https://doi.org/10.1186/s12929-024-01069-8.

APA

Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Jun Hyoung Park, Chinmay Chowdhury, Mohiuddin Quadir, Soumyabrata Banerjee, Arghadip Choudhury, Soumik Laha, Nayim Sepay, Priyanka Boro, Benny Abraham Kaipparettu, & Biswajit Mukherjee. (2024). EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment. Journal of Biomedical Science, 31(1), 1–29. https://doi.org/10.1186/s12929-024-01069-8

Chicago

Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Jun Hyoung Park, Chinmay Chowdhury, Mohiuddin Quadir, Soumyabrata Banerjee, et al. 2024. “EpCAM-Targeted Betulinic Acid Analogue Nanotherapy Improves Therapeutic Efficacy and Induces Anti-Tumorigenic Immune Response in Colorectal Cancer Tumor Microenvironment.” Journal of Biomedical Science 31 (1): 1–29. doi:10.1186/s12929-024-01069-8.